Lutris Pharma to Present Phase 2 Results of Novel B-Raf Inhibitor for EGFR Inhibitor-Induced Skin Rash at AACR 2025
Lutris Pharma will present results from a Phase 2 trial of LUT014, a topical B-Raf inhibitor for EGFR inhibitor-induced acneiform rash, at the AACR Annual Meeting in Chicago this April.
PPP2R1A Mutations Linked to Better Survival in High-Risk Endometrial Cancer Patients on Immunotherapy
Patients with PPP2R1A-mutated endometrial cancer showed significantly improved survival on lenvatinib-pembrolizumab combination therapy compared to those with wild-type PPP2R1A.
Promising Results for HER2-Targeted Therapy in Previously Treated Breast Cancer Patients
A combination of tucatinib and trastuzumab demonstrated significant efficacy, achieving 42% tumor shrinkage in HER2-negative breast cancer patients with specific HER2 mutations.
Integrated Smoking Cessation Program Shows Superior Results in Lung Cancer Screening Setting
A randomized trial at MD Anderson Cancer Center demonstrates that integrating smoking cessation services within lung cancer screening programs achieved 37.1% abstinence rates at 3 months, significantly outperforming standard quitline referrals.
LumiSystem Shows Promise in Reducing Radiation Need After Breast Cancer Lumpectomy
A new study presented at SABCS 2024 demonstrates that LumiSystem, combining Lumicell Direct Visualization System and pegulicianine, can help achieve broader surgical margins during lumpectomy procedures. The technology enabled 46.5% of patients to receive additional guided excisions, potentially reducing or eliminating the need for radiation therapy in select breast cancer patients.
Chemo-Free Ponatinib and Blinatumomab Show Promise in Ph+ ALL
A chemotherapy-free regimen of ponatinib and blinatumomab demonstrates high rates of deep minimal residual disease (MRD) negativity in newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL).
NKT2152 Shows Promise as HIF-2α Inhibitor in Advanced Clear Cell Renal Cell Carcinoma
Data from an ongoing phase 1/2 study reveals that NKT2152, an oral HIF-2α inhibitor, exhibits strong anti-tumor activity in heavily pretreated advanced clear cell renal cell carcinoma patients.
Relaxed Trial Criteria Show Promise for AML and MDS Patients
A clinical trial demonstrated the feasibility of including acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) patients with comorbidities typically excluded from standard trials.